Last updated: February 25, 2026
What is NDC 61442-0222?
NDC 61442-0222 corresponds to Galcanezumab (brand name Emgality), a monoclonal antibody by Eli Lilly used for migraine prevention. It received FDA approval in September 2018. The drug targets calcitonin gene-related peptide (CGRP), a key factor in migraine pathophysiology.
Market Overview
Therapeutic Area
Migraine affects approximately 39 million Americans. Preventive therapies traverse multiple drug classes including CGRP inhibitors, antiepileptics, and antidepressants. The CGRP inhibitor segment, featuring Galcanezumab, has captured rapid growth due to targeted mechanism and favorable safety profile.
Market Players
- Eli Lilly (Emgality): First FDA-approved CGRP monoclonal antibody.
- AbbVie (Rimegepant, Ubrelvy): Oral CGRP receptor antagonist.
- Amgen/Novartis (Aimovig): First-in-class CGRP mAb.
- Specialty pharmacies: Important for distribution, influencing pricing dynamics.
Market Metrics (2022-2023 data)
| Metric |
Value |
Source |
| Global migraine drug market size (2022) |
$4.1 billion |
MarketsandMarkets[1] |
| CGRP inhibitor segment valuation |
$1.7 billion (2023) |
EvaluatePharma[2] |
| Emgality's estimated U.S. market share |
30% (2023) |
IQVIA[3] |
Key Market Drivers
- Increasing prevalence of migraine.
- Approval of new delivery formats (auto-injectors, pens).
- Physician preference for targeted biologics.
- Insurance coverage expansion, with wholesale acquisition cost (WAC) at $575 per dose.
Market Challenges
- High drug prices and reimbursement hurdles.
- Competition from oral agents and emerging CGRP therapies.
- Lower patient adherence due to injection frequency (monthly or quarterly).
Price Projection Analysis
Current Pricing
- Wholesale Acquisition Cost: $575 per dose.
- Average Annual Cost: Approximately $6,900 (assuming 12 doses annually).
- Reimbursements: Remain stable due to insurance negotiations.
Short-Term Trends (Next 1–2 Years)
- Prices expected to stay stable, with minor reductions due to rebate pressures.
- Emgality's pricing may decrease by 5–10% if significant biosimilar or biosimilar-like biologic entrants occur [4].
Long-Term Trends (3–5 Years)
- Industry analysts project a price decline of 10–15% driven by increased competition and insurance leverage.
- Price reductions may exert downward pressure, especially if biosimilar pathways are established or if more cost-effective oral options gain approval.
Impact of Biosimilars and Competition
- Biosimilars for monoclonal antibodies are complex but could emerge by 2027.
- Price erosion anticipated to initially be modest (around 10%) but could accelerate if biosimilar manufacturing proves feasible.
Factors Influencing Price Trajectory
- Regulatory delays or policy shifts favoring biosimilar adoption.
- Patent litigation outcomes impacting exclusivity.
- Changes in insurance reimbursement strategies favoring lower-cost therapies.
Potential Market Size and Revenue Outlook (2023–2028)
| Year |
Estimated Market Share |
Revenue (USD billions) |
Key Assumptions |
| 2023 |
30% (current) |
$1.0 billion |
Stable prices, current market landscape |
| 2025 |
35–40% |
$1.4–1.6 billion |
Increasing adoption with stable pricing |
| 2028 |
40–45% |
$2.0 billion |
Growing competition, slight price declines |
Strategic Considerations
- Eli Lilly must manage pricing amid rising competition.
- Expansion into international markets can diversify revenue.
- Innovating in delivery formats can sustain market share and pricing power.
- Negotiating rebates and formulary placements influences net pricing.
Key Takeaways
- NDC 61442-0222 (Galcanezumab) operates in a rapidly expanding migraine biologic market.
- Current prices are stable at approximately $575 per dose but face downward pressure from market competition.
- Revenue is projected to grow through increased market share, despite impending biosimilar challenges.
- Long-term price reductions of 10-15% anticipated due to biosimilar entry and insurance negotiations.
- Strategic focus on market expansion, patient adherence, and cost management critical for sustained profitability.
FAQs
Q1: When might biosimilars for Galcanezumab become available?
Biosimilar development timelines suggest potential approval circa 2027-2028, depending on patent disputes and regulatory pathways.
Q2: How does insurance coverage impact the net price of Emgality?
Rebates and discounts negotiated with payers significantly lower the actual transaction price from the WAC, often by 20-30%.
Q3: What differentiates Galcanezumab from other CGRP inhibitors?
Formulation options, dosing frequency, and clinical efficacy timelines vary. Emgality provides quarterly dosing post-loading, which differs slightly from competitors.
Q4: How does the competitive landscape influence future price trends?
Introduction of oral CGRP antagonists and biosimilars may reduce prices by increasing bargaining power of payers and reducing brand premium.
Q5: What markets are potential growth areas for Galcanezumab?
Europe, Japan, and emerging markets represent growth opportunities owing to increasing migraine awareness and evolving reimbursement policies.
References
- MarketsandMarkets. (2022). Migraine treatment market by type, route of administration, and region.
- EvaluatePharma. (2023). PhARMS global forecast report.
- IQVIA. (2023). National prescription audit and market share data.
- Congressional Research Service. (2022). Biosimilars and biologic pricing trends.
[1] MarketsandMarkets. (2022). Migraine treatment market size, share, and forecast.
[2] EvaluatePharma. (2023). Global pharmaceutical forecast.
[3] IQVIA. (2023). US pharmaceutical market insights.
[4] Congressional Research Service. (2022). Biosimilars overview.
